Showing results (211-220 of 350) with videos related to
Sort By:
Pageof 35
Clinical Immunology (Orlando, Fla.)|April 20, 2004
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasisAlice B Gottlieb, Sewon Kang, Kenneth G Linden, et al.International Journal of Cancer|April 1, 2005
Combined subcarcinogenic benzo[a]pyrene and UVA synergistically caused high tumor incidence and mutations in H-ras gene, but not p53, in SKH-1 hairless mouse skinYongyin Wang, Dayuan Gao, David P Atencio, et al.Dermatology and Therapy|February 27, 2021
Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry DermatologistsBruce Strober, Nirali Kotowsky, Rose Medeiros, et al.Drugs - Real World Outcomes|June 24, 2024
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis RegistryMark Lebwohl, Bruce Strober, Amy Schrader, et al.Dermatology and Therapy|February 22, 2026
Systemic Corticosteroid Exposure in Patients with Atopic Dermatitis: A US Population-Based StudyChristopher G Bunick, Ruth Ann Vleugels, Mark Lebwohl, et al.Journal of the American Academy of Dermatology|April 14, 2018
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasisClaus Zachariae, Kenneth Gordon, Alexandra B Kimball, et al.Journal of Drugs in Dermatology : JDD|May 6, 2025
Efficacy and Safety of Hedgehog Inhibitors for Advanced Basal Cell Carcinoma: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.Journal of the American Academy of Dermatology|April 17, 2018
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)Mark Lebwohl, Andrew Blauvelt, Carle Paul, et al.Free Radical Biology & Medicine|October 11, 2005
Benzo[a]pyrene and its metabolites combined with ultraviolet A synergistically induce 8-hydroxy-2'-deoxyguanosine via reactive oxygen speciesDayuan Gao, Yunjing Luo, Denise Guevara, et al.Journal of the American Academy of Dermatology|October 4, 2005
Oral phosphate binders in the treatment of pseudoxanthoma elasticumDaniel W Sherer, Giselle Singer, Jaime Uribarri, et al.Pageof 35